The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap

Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap

May 15, 2020 • By Vania Lin, MD, MPH, & Leah Krull, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Clinically amyotrophic dermatomyositis (CADM), a subset of dermatomyositis (DM), is a rare autoimmune disease characterized by typical DM cutaneous findings (e.g., heliotrope rash, Gottron papules, Gottron sign) without evidence of myositis.1 The incidence of DM and CADM is approximately 9.63 per 1 million people and 2.08 per 1 million people, respectively.2 The association with development of interstitial lung disease (ILD) and an increased risk of malignancy highlights the importance of prompt diagnosis, disease management and appropriate malignancy screening.

You Might Also Like
  • A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis
  • Case Report: A Patient’s Clubbing & Arthralgias Resist Diagnosis
  • Case Report: A Patient Develops Scleroderma Renal Crisis
Explore This Issue
May 2020

Due to the rarity of CADM, hetero­geneity of disease manifestation and recalcitrant nature of the disease, treatment remains challenging; possible overlap with other autoimmune diseases complicates management. However, the advent of immunotherapy has introduced new possibilities in modifying disease progression.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Here, we describe a case of a patient with CADM, associated ILD and concurrent rheumatoid arthritis (RA) who was successfully treated with a combination of conventional and biologic therapy.

Case Description

Our patient is a 65-year-old woman who works as a fitness instructor. She had no significant past medical history prior to presenting for rheumatological evaluation with a three-month history of rash, and bilateral hand swelling and pain. Her initial symptoms manifested as non­blanching, erythematous, papular lesions along the palmar aspects of the hands and digits, along with periungual erythema. These symptoms resolved after a few weeks, but returned after a month, this time with a new, annular, hyperpigmented patch on the upper left cheek as well. The patient also experienced diffuse swelling, pain and morning stiffness of the proximal and distal interphalangeal joints of the hands. She noted the development of constitutional symptoms, including fatigue and a 30 lb. weight loss, as well as progressive shortness of breath, subjective weakness of the upper extremities and new-onset Raynaud’s phenomenon.

The initial physical examination was significant for a nonblanching, papular rash along the palmar aspects of the hands and digits, periungual erythema, and edema and tenderness of the proximal and distal interphalangeal joints of the hands.

The initial physical examination was significant for a nonblanching, papular rash along the palmar aspects of the hands and digits, periungual erythema, and edema and tenderness of the proximal and distal interphalangeal joints of the hands.

The patient went to the emergency department multiple times for these symptoms, which improved with short courses of prednisone, but recurred each time after completion of treatment. A chest X-ray was consistent with hyperinflation of the lungs, with apparent scarring of the bases. A computed tomography scan (CT) of the abdomen and pelvis showed an 8 mm enhancing lesion in the right hepatic lobe, suggestive of a hemangioma, as well as streaky opacities in the bilateral lung bases. Autoimmune workup showed an erythro­cyte sedimentation rate (ESR) of 28 mm/hour, no elevation of C-reactive protein, rheumatoid factor (RF) of 37.9 IU/mL, anti-cyclic citrullinated peptide (anti-CCP) antibody >250 u/mL, and undetectable anti-nuclear antibodies, anti-double stranded DNA, anti-Smith and anti-RNP antibodies (see Table 1, opposite).

At the time of the initial rheumatological evaluation, the patient remained significantly symptomatic, with persistent rash and severe hand and knee joint swelling and pain. Further workup showed elevated ESR of 45 mm/hour, normal creatinine kinase and aldolase levels, negative anti-Jo-1 antibody, and increased kappa and lambda light chains with preserved ratio and mixed glomerular and tubular proteinuria on serum and urine protein electrophoresis. X-rays of both hands showed sclerosis, lucencies of the lunates and degenerative changes without apparent erosion.

The patient was started on 200 mg of hydroxychloroquine daily, along with 40 mg of prednisone daily, for treatment of RA. Additional immunosuppressive therapy was held, pending further pulmonary and hematological investigations and age-appropriate cancer screening.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The concurrent manifestations of rash and rapidly declining pulmonary function without significant musculoskeletal symptoms increased our suspicion for overlap with CADM. A subsequent anti-melanoma differentiation-associated protein 5 (anti-MDA5) assay returned positive, which further supported this diagnosis.

An extensive workup was carried out to better characterize the disease and rule out possible concurrent systemic processes. Compared with the CT of the abdomen and pelvis performed one month before, chest CT images showed significant progression of her pulmonary disease, including diffuse nodular and coalescing opacities involving the lungs fairly symmetrically, from the pulmonary parenchyma, subpleural upper lobes, portions of the middle lobe and the lingula to the bibasilar regions. No suspicious or dominant nodules were apparent.

A pulmonary function test showed normal total lung capacity at 100%, and reduced carbon monoxide diffusing capacity at 64%. A ventilation-perfusion scan demonstrated a low likelihood for pulmonary embolism. A transthoracic echocardiogram showed preserved cardiac function, with left ventricular ejection fraction of 70% and no apparent pulmonary hypertension or valvular dysfunction.

Table 1: Laboratory Tests

TestResultUnitsReference Interval
Erythrocyte sedimentation rate28, increased to 45mm/hr0–40
C-reactive protein0.8mg/L0.0–4.9
Creatinine kinase142U/L24–173
Aldolase8U/L3.3–10.3
Complement C3102mg/dL82–167
Complement C431mg/dL14–44
Rheumatoid factor37.9IU/mL0.0–13.9
Anti-cyclic citrullinated peptide antibodies>250Units0–19
Anti-melanoma differentiation-associated protein 5 antibodiesPositive-Negative
Anti-nuclear antibodiesNegative-Negative
Anti-double-stranded DNA antibodies<1IU/mL<5
Anti-Smith antibodies<0.2AI0.0–0.9
Anti-Jo-1 antibodies<0.2AI0.0–0.9
Anti-chromatin antibodies0.2AI0.0–0.9
RNP antibodies0.3AI0.0–0.9
Anti-SSA antibodies<0.2AI0.0–0.9
Anti-SSB antibodies<0.2AI0.0–0.9
Anti-scleroderma-70 antibodies<0.2AI0.0–0.9
Anti-centromere B antibodies<0.2AI0.0–0.9
Anti-myeloperoxidase antibodies<9U/mL0.0–9.0
Anti-proteinase 3 antibodies<3.5U/mL0.0–3.5
Anti-cardiolipin IgG<9GPL U/mL<15
Anti-cardiolipin IgM<9MPL U/mL<13
Beta-2 glycoprotein I IgG<9GPI IgG units0–20
Beta-2 glycoprotein I IgM<9GPI IgM units0–32
Thyroid peroxidase antibody31IU/mL0–34
Thyroglobulin antibody<1.0IU/mL0.0–0.9
Serum protein electrophoresis
Albumin3.2g/dL2.9–4.4
Alpha-1-globulin0.3g/dL0.0–0.4
Alpha-2-globulin0.8g/dL0.4–1.0
Beta globulin1.1g/dL0.7–1.3
Gamma globulin1.7g/dL0.4–1.8
M-spike0.1g/dLNot observed
Globulin, total3.9g/dL2.2–3.9
A/G ratio0.80.7–1.7
Serum immunofixation
Immunoglobulin G1547mg/dL700–1600
Immunoglobulin A370mg/dL87–352
Immunoglobulin M221mg/dL26–217
Immunofixation shows IgM monoclonal protein with lambda light chain specificity.

Bronchoscopy and lung biopsy showed nonspecific inflammation. Hematological and oncological investigations, including an unremarkable bone survey and negative colonoscopy and mammography, pointed to the diagnosis of monoclonal gam­mopathy of undetermined significance.

Taken all together, these findings were consistent with CADM with associated autoimmune ILD and no evidence of amyloidosis, infection or malignancy.

The patient was continued on 40 mg of prednisone daily and prophylactic trimethoprim and sulfamethoxazole; she was also started on 500 mg of mycophenolate mofetil (MMF) twice daily one month afterward (following the aforementioned testing), with the goal of titrating up to 3,000 mg daily for optimal control of her pulmonary disease.

Her shortness of breath, rash and synovial pain significantly improved on this regimen, but the rash and joint symptoms recurred with the tapering of prednisone. Thus, rituximab was initiated at 1,000 mg on days 1 and 15, and every six months thereafter, which has helped maintain adequate control of her joint and pulmonary symptoms.

At follow-up six months from the initial rheumatological evaluation, the patient continues to do well on this regimen, with successful taper of prednisone down to 5 mg daily, and discontinuation of prophylactic antibiotics.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Clinically Amyotrophic Dermatomyositis (CADM), combination therapy, interstitial lung disease (ILD)Issue: May 2020

You Might Also Like:
  • A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis
  • Case Report: A Patient’s Clubbing & Arthralgias Resist Diagnosis
  • Case Report: A Patient Develops Scleroderma Renal Crisis
  • Case Report: Cardiac Tamponade in a Rheumatoid Arthritis Patient

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.